top
Please input keywords
Database
News events
Contact us
EN
CN
JP
KR
About us
Introduction
History
Management team
Culture
Social Responsibility
Join us
Antibody R&D
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
Animal models
Pharmacology service
Gene Editing
Collaborations
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
Collaborations
Collaborations
Advancing innovative drug R&D through partnership
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Antibody Out-licensing
Antibody Co-Development
Antibody Transfer
Technology Platform Out-licensing
Various drug modalities
Monoclonal Antibody
Bispecific Antibody
Bispecific ADC
Nanobodie
TCRm Antibody
Cell Therapy
Established partnerships
50
50 therapeutic antibody co-development/out-licensing/transfer agreements
42
42 target-nominated RenMice licensing projects
5
5 pipeline-based co-development
Disclosed Partners
Worldwide antibody assets or platform partners include Merck KGaA, Janssen, Xencor, ADC Therapeutics, RemeGen and BeiGene.
Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.
Antibody Discovery Platforms
+86-010-56967680
info@bbctg.com.cn
010-56967601
ir@bbctg.com.cn
Copyright © 2022 Biocytogen. All Rights Reserved
Powered by Fractal-technology